Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 First patient exceeding 5-year complete remission after 225Ac-PSMA-TAT.

Literature DB >> 32468252

First patient exceeding 5-year complete remission after ²²⁵Ac-PSMA-TAT.

Hendrik Rathke¹, Frank Bruchertseifer², Clemens Kratochwil³, Hanno Keller⁴, Frederik L Giesel^3,5, Christos Apostolidis², Uwe Haberkorn^3,5, Alfred Morgenstern².

Abstract

Entities: Chemical Species

Year: 2020 PMID： 32468252 DOI： 10.1007/s00259-020-04875-y

Source DB: PubMed Journal: Eur J Nucl Med Mol Imaging ISSN： 1619-7070 Impact factor: 9.236

× No keyword cloud information.

3 in total

1. Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with ²²⁵Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control.

Authors: Clemens Kratochwil; Frank Bruchertseifer; Hendrik Rathke; Markus Hohenfellner; Frederik L Giesel; Uwe Haberkorn; Alfred Morgenstern
Journal: J Nucl Med Date: 2018-01-11 Impact factor: 10.057

2. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.

Authors: Lisa Bodei; Marta Cremonesi; Mahila Ferrari; Monica Pacifici; Chiara M Grana; Mirco Bartolomei; Silvia M Baio; Maddalena Sansovini; Giovanni Paganelli
Journal: Eur J Nucl Med Mol Imaging Date: 2008-04-22 Impact factor: 9.236

3. ²²⁵Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study.

Authors: Mike Sathekge; Frank Bruchertseifer; Otto Knoesen; Florette Reyneke; Ismaheel Lawal; Thabo Lengana; Cindy Davis; Johncy Mahapane; Ceceila Corbett; Mariza Vorster; Alfred Morgenstern
Journal: Eur J Nucl Med Mol Imaging Date: 2018-09-19 Impact factor: 9.236

3 in total

Review 1. Progress in Targeted Alpha-Particle-Emitting Radiopharmaceuticals as Treatments for Prostate Cancer Patients with Bone Metastases.

Authors: Chirayu M Patel; Thaddeus J Wadas; Yusuke Shiozawa
Journal: Molecules Date: 2021-04-09 Impact factor: 4.411

2. Dosing ²²⁵Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity.

Authors: Clemens Kratochwil; Leonidas Apostolidis; Hendrik Rathke; Christos Apostolidis; Felix Bicu; Frank Bruchertseifer; Peter L Choyke; Uwe Haberkorn; Frederik L Giesel; Alfred Morgenstern
Journal: Eur J Nucl Med Mol Imaging Date: 2021-08-26 Impact factor: 9.236

Review 3. Global experience with PSMA-based alpha therapy in prostate cancer.

Authors: Mike M Sathekge; Frank Bruchertseifer; Mariza Vorster; Alfred Morgenstern; Ismaheel O Lawal
Journal: Eur J Nucl Med Mol Imaging Date: 2021-06-26 Impact factor: 9.236

3 in total

First patient exceeding 5-year complete remission after 225Ac-PSMA-TAT.

1. Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control.

2. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.

3. 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study.

Review 1. Progress in Targeted Alpha-Particle-Emitting Radiopharmaceuticals as Treatments for Prostate Cancer Patients with Bone Metastases.

2. Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity.

Review 3. Global experience with PSMA-based alpha therapy in prostate cancer.

First patient exceeding 5-year complete remission after ²²⁵Ac-PSMA-TAT.

1. Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with ²²⁵Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control.

3. ²²⁵Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study.

2. Dosing ²²⁵Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity.